MedShr Learning

MedShr Learning Designed by doctors, for doctors, MedShr Learning has over 800 learning modules in all specialties.

ACC.26 IMPEDENCE-HFpEF - CardioSet Lung Impedence guided management reduces HFpEF hospitalisationIMPEDANCE-HFpEF: a rand...
29/03/2026

ACC.26 IMPEDENCE-HFpEF - CardioSet Lung Impedence guided management reduces HFpEF hospitalisation

IMPEDANCE-HFpEF: a randomized trial testing whether non-invasive lung impedance monitoring can guide diuretic therapy in HFpEF — and the results are remarkable. In 150 patients followed for a mean of 38 months, lung impedance–guided management reduced HF hospitalizations by 81% (HR 0.19; P

ACC.26: PRO-TAVI - PCI can safely be deferred until after TAVIPRO-TAVI: the first RCT to show that PCI can safely be def...
29/03/2026

ACC.26: PRO-TAVI - PCI can safely be deferred until after TAVI

PRO-TAVI: the first RCT to show that PCI can safely be deferred in TAVI patients with concomitant coronary artery disease. In 466 elderly patients across 12 Dutch centres, a TAVI-first strategy was noninferior to routine pre-TAVI revascularization for the composite of death, MI, stroke, or major bleeding at 1 year (24.1% vs 25.8%; rate difference −1.7 pp; P

ACC.26: TRI-FR - TEER gives long terms improves in outcomesTRI-FR extended follow-up: the first RCT to show transcathete...
29/03/2026

ACC.26: TRI-FR - TEER gives long terms improves in outcomes

TRI-FR extended follow-up: the first RCT to show transcatheter tricuspid repair delivers long-term outcome benefit. At a median follow-up of ~35 months, T-TEER added to medical therapy reduced the composite of first HF hospitalization, tricuspid surgery, or CV death by 44% (HR 0.56; 95% CI 0.36–0.88; P=0.0109) and halved recurrent HF hospitalizations (rate ratio 0.52; P=0.0073). Benefit emerged beyond year 1 — reframing severe TR from a passive marker to a treatable driver of right-sided heart failure.



Visit MedShr to listen, read more, and join the discussion.

ACC.26: ALL RISE - Cathworks FFRangio is non-inferior to invasive FFRALL-RISE delivers landmark evidence for wire-free c...
29/03/2026

ACC.26: ALL RISE - Cathworks FFRangio is non-inferior to invasive FFR

ALL-RISE delivers landmark evidence for wire-free coronary physiology: in 1,930 patients across 59 international sites, a treatment strategy guided by angiography-derived FFR was noninferior to pressure wire–guided physiology for 1-year MACE (6.9% vs 7.1%; HR 0.98; 95% CI 0.70–1.39; P=0.0008 for noninferiority). Assessment was faster (6 vs 8 min), with shorter procedure times, less fluoroscopy, and lower contrast volume. Published simultaneously in NEJM.

ACC.26 ORBITA CTO - placebo controlled trial shows CTO PCI improves symptomsORBITA-CTO delivers landmark evidence: in th...
29/03/2026

ACC.26 ORBITA CTO - placebo controlled trial shows CTO PCI improves symptoms

ORBITA-CTO delivers landmark evidence: in the first randomized, double-blind, placebo-controlled trial of CTO PCI, recanalization significantly improved the angina symptom score (OR 4.38; 95% CrI 1.57–12.69; Pr[Benefit] = 99.6%). Patients undergoing CTO PCI experienced 30.6 additional angina-free days over 6 months, with consistent improvements across SAQ domains and CCS class. Blinding was rigorously maintained. Published simultaneously in JACC.



Visit MedShr to listen, read more, and join the discussion.

CHIP-BCIS3 delivers a sobering result: in 300 patients with severe LV dysfunction undergoing complex PCI, routine electi...
29/03/2026

CHIP-BCIS3 delivers a sobering result: in 300 patients with severe LV dysfunction undergoing complex PCI, routine elective mechanical circulatory support did not reduce the primary hierarchical composite outcome (win ratio 0.85; P=0.30). Cardiovascular death was significantly higher in the pump group — 26.7% vs 14.5% (HR 1.91; P=0.018). The first randomized trial of elective pump-supported high-risk PCI challenges current practice. Published simultaneously in the NEJM.



Visit MedShr to listen, read more, and join the discussion.

ACC26: HI-PEITHO - EKOS catheter directed thrombolysis improved outcomes in PEHI-PEITHO delivers landmark results: ultra...
29/03/2026

ACC26: HI-PEITHO - EKOS catheter directed thrombolysis improved outcomes in PE

HI-PEITHO delivers landmark results: ultrasound-facilitated catheter-directed fibrinolysis reduced the composite of PE-related death, cardiorespiratory decompensation and recurrence by 61% compared with anticoagulation alone in intermediate-risk PE patients. The safety profile was reassuring — with no intracranial haemorrhage in either group. This is the first randomized trial to show clinical benefit for any catheter-based PE intervention. Published simultaneously in the NEJM.



Visit MedShr to listen, read more, and join the discussion.

29/03/2026

STEMI-DTU Trial - Up front Impella in Anterior STEMI without shock did not reduce infarct size

STEMI-DTU delivers a nuanced negative: mechanical ventricular unloading before PCI did not reduce infarct size in 527 anterior STEMI patients without shock. But the real story lies in the timing data - despite 47 minutes of additional ischaemia from the protocolized delay, infarct sizes were remarkably similar between groups. Published simultaneously in JACC, this pivotal trial challenges assumptions about ischaemic time while raising important questions about patient selection and device evolution.



Visit MedShr to listen, read more, and join the discussion.

29/03/2026

ACC26: CHAMPION-AF Trial shows LAA non-inferior to DOACs in non-valvular AF

CHAMPION-AF rewrites the playbook on atrial fibrillation management. In 3,000 patients suitable for long-term blood thinners, left atrial appendage closure proved noninferior for preventing stroke, CV death, and systemic embolism - while nearly halving bleeding risk at 3 years. Published simultaneously in NEJM, this trial opens the door to shared decision-making for a much broader AF population.



Visit MedShr to listen, read more, and join the discussion.

13/03/2026

UK CARDIO-IMID Partnership | New Course Now Live on MedShr! 🎉
We're excited to announce that the introductory course on Cardio-Rheumatology is now live on MedShr — direct from the UK CARDIO-IMID Partnership meeting in Edinburgh!
Whether you're already a MedShr member or joining for the first time, access is easy: ✅ Sign in with your existing account, or ✅ Use your NHS or academic email for instant access
The course is free, self-paced, and fully compliant — covering clinical case discussion and e-learning modules designed for clinicians.
👉 Sign up and explore: https://medshr.it/Cardio-IMID
We'd love to hear what you think — drop your feedback in the comments below!

Address

London

Telephone

+442031370195

Website

Alerts

Be the first to know and let us send you an email when MedShr Learning posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The School

Send a message to MedShr Learning:

Shortcuts

Share

Category